4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
Recent tariff changes and trade frictions have disrupted that advantage and slowed growth. However, CETTIRE’s flexible, low-cost structure suggests its core model remains intact, leaving the company with meaningful long-term profit potential despite the current uncertainty around customer growth and demand.
Invictus Energy is an early-stage oil and gas explorer in Zimbabwe with large but unproven resource potential. With no revenue and heavy funding needs, the stock offers significant upside if discoveries succeed, but remains a high-risk, news-driven investment.
Liontown Resources has rallied on stronger lithium prices, improving production at Kathleen Valley, and a healthier balance sheet after reducing debt. Rising EV and battery demand plus new offtake deals have lifted sentiment. The stock is now approaching key resistance around A$2.20, where the next breakout or pullback will likely be decided.
Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.
PlaySide Studios is shifting from contract development to original IP and publishing to boost margins and growth. Strong partnerships and a solid pipeline support optimism, but revenue volatility and past unprofitability keep investor sentiment cautious.
